Intended for healthcare professionals
Re: Correspondence with the National Institute for Health and Clinical Excellence
In this letter from BMJ editor in chief Fiona Godlee asks NICE chair Michael Rawlins why NICE does not require access to all the clinical trial data on a drug when it is making a decision to approve the drug for purchase by the NHS.
